Compound Glycyrrhizin Tablets

1. Anti-inflammatory effect: 1) Anti-allergic effect Glycyrrhizic acid glycoside has anti-allergic effects such as inhibiting local allergic necrosis reaction (Arthus Phenomenon) and inhibiting Schwartzman Phenomenon in rabbits. For corticosteroids, it enhances the hormone's stress response inhibition effect and antagonizes the hormone's anti-granulation and thymus atrophy effect. It has no effect on the exudation of hormones. 2) Inhibition of arachidonic acid metabolic enzymes Glycyrrhizic acid glycoside can directly bind to phospholipase A2, the initiator enzyme of the arachidonic acid metabolic pathway, and to lipoxygenase, which acts on arachidonic acid to produce inflammatory mediators, selectively inhibiting the phosphorylation of these enzymes and inhibiting their activation. 2. Immunomodulatory effect: Glycyrrhizic acid glycoside has the following immunomodulatory effects in in vitro experiments: 1) Regulation of T cell activation; 2) Induction of gamma interferon; 3) Activation of NK cells; 4) Promoting differentiation of extrathymic T lymphocytes. 3. Inhibition of experimental hepatocyte damage. In the rat hepatocyte cell line cultured in invitro, glycyrrhizic acid glycoside inhibited hepatocyte damage caused by carbon tetrachloride. 4. Inhibition of viral proliferation and inactivation of viruses. In the mouse MHV (mouse hepatitis virus) infection experiment, the administration of glycyrrhizic acid glycoside can prolong its survival days; in the rabbit vaccinia virus (Vacciniavirus) pox prevention experiment, it has the effect of preventing pox; in the in vitro experimental system, the inhibition of the proliferation of herpes viruses and the inactivation of viruses were also observed. It has been reported that glycine and methionine can inhibit the reduction of urine volume and sodium excretion caused by oral administration of glycyrrhizic acid glycoside to rats. 5. Non-clinical toxicology study. Acute toxicity: 12g (48 tablets) of this product per kg body weight was orally administered to rats, and no mortality was observed, so the LD50 cannot be calculated. LD50>12g (48 tablets).

This product is a compound preparation, and its components (per tablet) are: glycyrrhizic acid glycoside, glycyrrhizic acid monoammonium salt, glycine, and methionine.

This product is a film-coated tablet, which appears off-white after removing the coating.

Compound Glycyrrhizic Acid Tablets, treat chronic liver disease, improve liver function abnormalities. Can be used to treat eczema, dermatitis, and alopecia areata.

Adults usually take 2 to 3 tablets at a time, and children take 1 tablet at a time, 3 times a day, orally after meals. The dosage can be increased or decreased according to age and symptoms.

The actual frequency of adverse reactions in the use of this preparation has not yet been investigated. Important adverse reactions: 1. Pseudoaldosteronism (frequency unknown): Symptoms of pseudoaldosteronism such as hypokalemia, increased blood pressure, sodium and fluid retention, edema, decreased urine volume, and weight gain may occur. Therefore, during medication, attention should be paid to observation (serum potassium value, etc.). If abnormal conditions are found, medication should be stopped. 2. Symptoms of rhabdomyolysis such as weakness, low muscle strength, muscle pain, limb cramps, and paralysis may also occur. If CK (CPK) is found to be elevated and myoglobin in blood and urine is elevated, the drug should be discontinued and appropriate treatment should be given.

1. Patients with aldosteronism, myopathy, and hypokalemia (can aggravate hypokalemia and hypertension). 2. Patients with advanced liver cirrhosis who have a tendency to have elevated blood ammonia (the methionine metabolites contained in this preparation can inhibit urea synthesis, thereby reducing the ability to handle ammonia).

Precautions for children: There are no studies on pharmacology, toxicology or pharmacokinetics that differ from those for adults. For drug use, please refer to [Usage and Dosage] and [Precautions]. Precautions for pregnancy and lactation: Pregnant and lactating women should be given the drug with caution after weighing the benefits of treatment outweigh the risks. Precautions for the elderly: Based on clinical application experience, the elderly are prone to adverse reactions of hypokalemia, so they need to be given with caution under close observation.

1. Attention should be paid when taking drugs together. 2. Drugs (loop diuretics, uric acid, furosemide, etc., thiazide and antihypertensive diuretics, trichloromethiazide, chlorthalidone, etc.) may cause hypokalemia (fatigue, low muscle strength), so pay full attention to observe the serum potassium value. 3. Mechanism and consequences: Diuretics can enhance the potassium excretion effect of glycyrrhizic acid contained in the preparation, which can further reduce serum potassium.

Store at room temperature (1-30℃).

Each tablet contains 25 mg of glycyrrhizic acid monoammonium salt (calculated as glycyrrhizin), 25 mg of glycine, and 25 mg of DL-methionine.

60 months.

Xinjiang Tefeng Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-25

• Address:

  China (Xinjiang) Pilot Free Trade Zone, No. 1036, Qingyang Road, Urumqi High-tech Industrial Development Zone (Xinshi District), Xinjiang

• Tax NO.:

  916501002999457537

• Registered Funds:

  62 million yuan

• Website:

  Log in to view

• Email:

  Log in to view